Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Argo Signs $4.2 Billion Agreement Selling Four RNA Candidates to Novartis

publication date: Jan 8, 2024

Shanghai Argo Biopharma entered two agreements with Novartis, out-licensing four next-gen RNAi therapeutics for $185 million upfront and a total value of $4.2 billion. In the first agreement, Argo granted Novartis exclusive global licenses to develop and commercialize a Phase 1 stage program. In addition, Argo will perform discovery and optimization on two Novartis-chosen cardiovascular targets, with Novartis owning an option to acquire a global license. In the second agreement, Argo granted Novartis an exclusive ex-Greater China license to a Phase I/IIa clinical-stage program for a cardiovascular therapy. Based on its cutting-edge RNAi platform, the assets offer promising efficacy and durability according to Argo. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here